Welcome to chemicalbook!
+1 (818) 612-2111
RFQ
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Analytical Chemistry>Standard>Pharmaceutical Impurity Reference Standards>Febuxostat Impurity
Febuxostat Impurity
  • Febuxostat Impurity
  • Febuxostat Impurity
  • Febuxostat Impurity
  • Febuxostat Impurity

Febuxostat Impurity NEW

Price Get Latest Price
Package 10mg 30mg 100mg
Min. Order: 10mg
Supply Ability: 1000000000
Update Time: 2025-07-31
Related documents: IR NMR COA MSDS

Product Details

Product Name: Febuxostat Impurity CAS No.: 2375033-35-3
Min. Order: 10mg Purity: 98
Supply Ability: 1000000000 Release date: 2025/07/31

Article illustration

Our products are mainly drug impurity reference products, drug standards, analytical chemistry, standard substances, organic chemical synthesis, chemical custom synthesis. For impurity localization, quantification, and quality control in drug development processes. Our laboratory area is more than 5000 square meters, we have more than 20 analytical instruments such as HPLC and MS/LC-MS/GC-MS, we also have TGA, IR and other testing instruments. We have the most advanced SFC preparation separation equipment.

All of our products include a complete set of structural confirmation maps. Such as COA, H-NMR,MASS,HPLC,UV,IR。The default HPLC purity of our products is not less than 95%. Particularly unstable products have a purity of no less than 90% and will be communicated to the customer in advance. we can also provide TGA,Q-NMR,C-NMR and so on。

Article illustration

Company Profile Introduction

-

You may like

Recommended supplier

Product name Price   Suppliers Update time
$0.00/25Kg/Drum
VIP5Y
WUHAN FORTUNA CHEMICAL CO., LTD
2021-09-09
$0.00/10mg
VIP2Y
ShenZhen H&D Pharmaceutical Technology Co., LTD
2024-07-10
$0.00/25Kg/Bag
VIP5Y
Sinoway Industrial co., ltd.
2022-08-08
$0.00/10mg
VIP2Y
ShenZhen H&D Pharmaceutical Technology Co., LTD
2024-07-04
INQUIRY